Biomarkers and Personalized Sorafenib Therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma.Cell death discovery · 2022
   Article
2. Genetic Landscape of Multistep Hepatocarcinogenesis.Cancers · 2022
   Review
3. Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib.Cancers · 2021
   Article
4. Color coded perfusion imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following trans-arterial chemoembolization (TACE) of hepatocellular carcinoma.PloS one · 2019
   Article
5. Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.Cancer science · 2017
   Article
6. Systemic treatment for hepatocellular carcinoma: Still unmet expectations.World journal of hepatology · 2017
   Review
7. Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience.OncoTargets and therapy · 2017
   Article
8. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.Scientific reports · 2016
   Article
9. Immune Checkpoint Blockade in Hepatocellular Carcinoma.Liver cancer · 2015
   Article
10. Yttrium-90 microsphere radioembolization for hepatocellular carcinoma.Liver cancer · 2015
    Review
11. Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe.Liver cancer · 2015
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.